drugset / Trial / NCT06112314
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
Timeline
- Start
- 2024-06-05
- Primary completion
- 2027-10-16
- Completion
- 2027-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brenetafusp | Protein / enzyme biologic | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Comparator | Relatlimab | Monoclonal antibody | 160 mg | — |